English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Aim: Cell cycle regulator  cyclin D1 (CCND1)  is a pivotal regulator for G1/S phase transition, playing a critical part in initiation of carcinogenesis. Triple negative breast cancer comprises a very heterogeneous group of cancer cells, but little is known about what is wrong in the genome of these patients. This study investigated contribution of  CCND1  genotype to individual triple negative breast cancer susceptibility.  Materials: In all, 2464 native Taiwan subjects consist of 1232 breast cancer cases and 1232 controls were enrolled in a hospital-based, case-control study.  CCND1  A870G (rs9344) genotyping was analyzed by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). Risk-stratified analyses correlated genotype and age-related characteristics of breast cancer subgroups.  Results: No significant difference was found between patient and control groups in distribution of genotypic and allelic frequencies in  CCND1  genotype, yet  CCND1  A870G (rs9344) GG genotype was far less prevalent in breast cancer patients younger than 55 years (OR=0.62, 95%CI=0.43–0.89,  P =0.0362), with first menarche earlier than 12.2 years (OR=0.61, 95% CI=0.42–0.87, P=0.0241), with menopause earlier than 49.0 years (OR=0.57, 95%CI=0.39–0.82,  P =0.0093), or showing triple-negative breast cancer (OR=0.28, 95%CI=0.13–0.62,  P =0.0006). Such valuable findings suggest  CCND1  A870G (rs9344) as a predictive marker for triple negative breast cancer in Taiwanese women; the authors sincerely hope these help us fight the toughest subtype in clinical management.

Contribution of personalized Cyclin D1 genotype to triple negative breast cancer risk